Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-Siglec-2/CD22 Antibody-FITC (3K479) is a FITC-conjugated Rabbit antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody-FITC (3K479) can be used in FCM.
Description | Anti-Siglec-2/CD22 Antibody-FITC (3K479) is a FITC-conjugated Rabbit antibody targeting Siglec-2/CD22. Anti-Siglec-2/CD22 Antibody-FITC (3K479) can be used in FCM. |
Ig Type | Monoclonal Rabbit IgG |
Clone | 3K479 |
Reactivity | Mouse |
Verified Activity | Flow cytometric analysis of Mouse CD22 expression on BABL/c splenocytes. Cells were stained with FITC-conjugated anti-Mouse CD22. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells. |
Application | FCM |
Recommended Dose | 5 μl/Test, 0.1 mg/ml |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse CD22 (rM CD22; TMPY-04083; BAE33829.1; Met1-Arg708) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
Purification | Protein A |
Appearance | Liquid |
Formulation | PBS solution containing 0.5% BSA and 0.09% sodium azide |
Research Background | CD22 is a member of the immunoglobulin superfamily, SIGLEC family of lectins. It is first expressed in the cytoplasm of pro-B and pre-B cells, and on the surface as B cells mature to become IgD+. CD22 serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. In addition to its potential role as a mediator of intercellular interactions, signal transduction through CD22 can activate B cells and modulate antigen receptor signaling in vitro. The phenotype of CD22-deficient mice suggests that CD22 is primarily involved in the generation of mature B cells within the bone marrow, blood, and marginal zones of lymphoid tissues. CD22 recruits the tyrosine phosphatase Src homology 2 domain-containing phosphatase 1 (SHP-1) to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and inhibits B-cell receptor (BCR)-induced Ca2+ signaling on normal B cells. CD22 interacts specifically with ligands carrying alpha2-6-linked sialic acids. As an inhibitory coreceptor of the B-cell receptor (BCR), CD22 plays a critical role in establishing signalling thresholds for B-cell activation. Like other coreceptors, the ability of CD22 to modulate B-cell signalling is critically dependent upon its proximity to the BCR, and this in turn is governed by the binding of its extracellular domain to alpha2,6-linked sialic acid ligands. However, genetic studies in mice reveal that some CD22 functions are regulated by ligand binding, whereas other functions are ligand-independent and may only require expression of an intact CD22 cytoplasmic domain at the B-cell surface. CD19 regulates CD22 phosphorylation by augmenting Lyn kinase activity, while CD22 inhibits CD19 phosphorylation via SHP-1.Cancer ImmunotherapyImmune CheckpointImmunotherapyTargeted Therapy |
Conjucates | FITC |
Others Formats | Unconjugated/APC/PE |
Antibody Types Available | 4 |
Immunogen | Recombinant Mouse CD22 Protein (TMPY-04083) |
Antigen Species | Mouse |
Biology Area | Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules |
Stability & Storage | Store at 2°C-8°C for 12 months, do not freeze. Keep away from direct sunlight. Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.